Cas:97239-80-0 1,1′-Bis(diisopropylphosphino)ferrocene manufacturer & supplier

Chemical Name:1,1′-Bis(diisopropylphosphino)ferrocene

CAS.NO:97239-80-0

Synonyms:1,1′-bis(diisopropylphosphino)ferrocene;MFCD02684559;1-(Diisopropylphosphino)-1,2,3,4,5-cyclopentanepentayl – iron (2:1);1,2,3,4,5-Cyclopentanepentayl, 1-[bis(1-methylethyl)phosphino]-, iron salt (2:1)

Molecular Formula:C₂₂H₃₆FeP₂

Molecular Weight:418.314

HS Code:

Physical and Chemical Properties:

Melting point:50-52 °C(lit.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:27.18000

Exact Mass:418.164154

LogP:6.72050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 1,1′-bis(diisopropylphosphino)ferrocene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3,4,5-Cyclopentanepentayl, 1-[bis(1-methylethyl)phosphino]-, iron salt (2:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3,4,5-Cyclopentanepentayl, 1-[bis(1-methylethyl)phosphino]-, iron salt (2:1) Use and application,1-(Diisopropylphosphino)-1,2,3,4,5-cyclopentanepentayl – iron (2:1) technical grade,usp/ep/jp grade.

Related News: Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. 1,1′-Bis(diisopropylphosphino)ferrocene manufacturer The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. 1,1′-Bis(diisopropylphosphino)ferrocene supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1,1′-Bis(diisopropylphosphino)ferrocene vendor Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. 1,1′-Bis(diisopropylphosphino)ferrocene factory The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful.